Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials01:16

Clinical Trials

10.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.9K
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.1K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.1K
Hazard Ratio01:12

Hazard Ratio

656
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
656
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

500
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
500
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

190
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
190
Preclinical Development: Overview01:28

Preclinical Development: Overview

6.1K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrated analysis of nutritional composition, phytochemical, and antioxidant activity in Cotoneaster microphyllus (Wall. ex Lindl.).

Scientific reports·2026
Same author

Atomic-Level Synergy of Dual Single-Atom Catalysts for Photocatalytic Hydrogen Evolution Reaction.

Small (Weinheim an der Bergstrasse, Germany)·2026
Same author

Silver nanoparticles biosynthesized by Citrobacter farmeri effectively inhibit growth and biofilm formation in Acinetobacter baumannii.

Microbial pathogenesis·2026
Same author

Deep brain stimulation for the treatment of paediatric dystonia due to neuroanatomical abnormalities: a systematic review of efficacy and future perspectives.

BMJ neurology open·2026
Same author

Global dataset of soil eukaryotic communities created with a uniform protocol and long read sequencing.

Scientific data·2026
Same author

Therapeutic potential of a novel spirocyclic molecule in a murine model of peripheral nerve injury mediated via anti-inflammatory and neuroprotective properties.

Molecular biology reports·2026
Same journal

LabSage: Structural-Semantic Decoupling for Enhanced Retrieval-Augmented Generation in Clinical Laboratories.

AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science·2026
Same journal

Evaluating Representation Embeddings from LLMs and Time-Series Foundation Models for Wearable Accelerometer-Based Health Prediction.

AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science·2026
Same journal

ClinNoteAgents: An LLM Multi-Agent System for Predicting and Interpreting Heart Failure 30-Day Readmission from Clinical Notes.

AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science·2026
Same journal

Mapping the Storm: Linking Tornado Paths to Emergency Room Surges Through Geocoded Patient Data.

AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science·2026
Same journal

Multi-Modal Deep Learning-Based Model to Predict Burkitt Lymphoma Recurrence.

AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science·2026
Same journal

A Multi-Model LLM Consensus Framework to Identify EHR-Predictable Eligibility Criteria in NSCLC Immunotherapy Trials.

AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science·2026
See all related articles

Related Experiment Video

Updated: Feb 24, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.4K

Clinical Trials.Gov: A Topical Analyses.

Vibha Anand1, Amos Cahan1, Soumya Ghosh1

  • 1IBM T.J. Watson Research Center, Cambridge, MA.

AMIA Joint Summits on Translational Science Proceedings. AMIA Joint Summits on Translational Science
|August 18, 2017
PubMed
Summary
This summary is machine-generated.

Analyzing 17 years of ClinicalTrials.gov data reveals evolving research trends. Cardiovascular, heart, brain, and pain management trials are increasing, while advanced cancer trials are declining.

More Related Videos

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.7K

Related Experiment Videos

Last Updated: Feb 24, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.4K
In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.7K

Area of Science:

  • * Clinical informatics and biomedical data science.
  • * Public health research and clinical trial analysis.

Background:

  • * ClinicalTrials.gov, a global clinical trial registry, was established in 2000, with mandatory registration commencing in 2008.
  • * Understanding the evolution of clinical trial topics over time is crucial for identifying knowledge gaps and research trends.

Purpose of the Study:

  • * To apply dynamic topic modeling (DTM) to analyze the evolution of clinical trial topics registered on ClinicalTrials.gov over a 17-year period.
  • * To identify shifts in research focus, including disease-specific, organ-specific, and general health trial areas.

Main Methods:

  • * Utilized dynamic topic modeling (DTM) to analyze metadata from registered clinical trials.
  • * Examined trial topics and their trends over the past 17 years.

Main Results:

  • * Identified distinct topic areas including 'Cardiovascular disorders,' 'Heart & Brain conditions,' and 'Breast & Prostate cancer,' alongside general health trials.
  • * Observed an upward trend in recent years for surgical, heart, brain, pain management, and general health trials.
  • * Noted a downward trend in advanced cancer trials.
  • * Found that general health trials are less frequently FDA-regulated.

Conclusions:

  • * Dynamic topic modeling provides unique insights into the evolution of clinical research areas.
  • * The findings highlight a shift in research focus, with increasing emphasis on cardiovascular, neurological, pain management, and surgical interventions.
  • * Identified declining interest in advanced cancer trials suggests a need for further investigation into research priorities and funding allocation.